Expression and significance of biglycan in endometrial cancer

Liu, Yang; Li, Weihua; Li, Xin; Tai, Yoshiaki; Lü, Qingtao; Yang, Ning; Jiang, Jie

doi:10.1007/s00404-013-3017-3

Cited by 46 publications

(43 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In previous study, we have confirmed that BGN is overexpressed in endometrial cancer [13]. In present study, we first screened the higher expression of BGN in several endometrial cancer cell types by Western blot, and then we explored the function of BGN in vitro and in vivo.…”

Section: Introductionsupporting

confidence: 68%

“…Our previous study has found that BGN was higher expressed in endometrial cancer cells, and we also know that carcinomatous stroma and the up-regulation of BGN was significantly associated with poor tumor differentiation and advanced stage of the tumor [13]. Growing evidence has demonstrated that BGN gene is overexpressed in various carcinoma tissues such as pancreatic adenocarcinoma [8], colon tumor [9], intrahepatic cholangiocarcinoma [11], gastric cancer [12], esophageal squamous cell carcinoma [14], and melanoma [15], which have something to do with disease progression in some respects.…”

Section: Discussionmentioning

confidence: 97%

See 1 more Smart Citation

Biglycan enhances the ability of migration and invasion in endometrial cancer

Sun

Wang

Han

et al. 2015

Arch Gynecol Obstet

Self Cite

View full text Add to dashboard Cite

show abstract

Section: Introductionsupporting

confidence: 68%

Section: Discussionmentioning

confidence: 97%

Biglycan enhances the ability of migration and invasion in endometrial cancer

Sun

Wang

Han

et al. 2015

Arch Gynecol Obstet

Self Cite

View full text Add to dashboard Cite

show abstract

“…In our study, the circulatory levels of Biglycan in patients were significantly elevated. Liu et al 23 observed a significantly higher circulatory levels of biglycan in endometrial carcinoma which correlated with poor prognosis. Also in our study, Biglycan mRNA fold expression and tissue Biglycan protein expression by IHC and western blotting in the tumour tissue were significantly higher than those in the adjacent normal tissue.…”

Section: Discussionmentioning

confidence: 99%

“…22 High expression of Biglycan in malignancy has been associated with poor prognosis as observed in endometrial cancer, oesophageal cancer and gastric cancer. [23][24][25] Knockdown of Biglycan using small interfering RNA (siRNA) in HCT116 colon cancer cell line inhibited cell proliferation and produced growth arrest. 26 As it also regulates the immune system, Biglycan has been found to be associated with auto-immune diseases like systemic lupus erythematosus (SLE) where it enhances the expression of CXCL13 which is a potent B cell chemo-attractant.…”

Section: Introductionmentioning

confidence: 99%

Altered expression of small leucine-rich proteoglycans (Decorin, Biglycan and Lumican): Plausible diagnostic marker in urothelial carcinoma of bladder

et al. 2017

View full text Add to dashboard Cite

Small leucine-rich proteoglycans are components of extracellular matrix that regulates neoplastic transformation. Among small leucine rich proteoglycans, Decorin, Biglycan and Lumican are most commonly implicated markers, and their expression is well studied in various malignancies. In this novel study, we have collectively evaluated expression of these three molecules in urothelial carcinoma of bladder. Thirty patients of confirmed untreated bladder cancer, 30 healthy controls for blood and 30 controls for adjacent non-tumour tissue were enrolled. Blood was collected from all subjects and tumour/adjacent normal tissue was obtained from the patients. Circulatory levels were estimated by enzyme-linked immunosorbent assay, relative messenger RNA expression by quantitative polymerase chain reaction and protein expression by immunohistochemistry and western-blotting. Circulatory levels of Biglycan (p = 0.0038) and Lumican (p < 0.0001) were significantly elevated, and that of Decorin (p < 0.0001) was significantly reduced in patients as compared with controls. Protein expression by immunohistochemistry and western-blotting showed elevated expression of Lumican and Biglycan and lower expression of Decorin in urothelial carcinoma of bladder. Quantitative polymerase chain reaction for messenger RNA expression from tissue specimens revealed significantly higher expression of Biglycan (p = 0.0008) and Lumican (p = 0.01) and lower expression of Decorin (p < 0.0001) in urothelial carcinoma of bladder. Out of all molecules receiver operating characteristic curve showed that the 0.207 ng/ml cut-off of serum Lumican provided optimum sensitivity (90.0%) and specificity (90.0%). Significant alteration of matrix small leucine-rich proteoglycans in urothelial carcinoma of bladder was observed. Higher expression of Lumican in Bladder cancer patients with the cut-off value of highest optimum sensitivity and specificity shows its importance as a potential non-invasive marker for early detection of UBC following further validation in large patient cohort.

show abstract

“…However, biglycan expression and serological levels of its processed byproducts correlate with the extent of liver fibrosis in murine models (108,204). Biglycan is also involved with progression and poor prognosis in a variety of malignancies such as gastrointestinal and endometrial cancers (7,122,221,377,415). In contrast, biglycan expression correlates with a favorable prognosis in bladder cancer where it seems to have an inhibitory effect on tumor cell proliferation (266).…”

Section: Proteoglycansmentioning

confidence: 99%

The wound healing, chronic fibrosis, and cancer progression triad

Rybinski

Franco‐Barraza

Cukierman

2014

Physiological Genomics

215

175

View full text Add to dashboard Cite

For decades tumors have been recognized as “wounds that do not heal.” Besides the commonalities that tumors and wounded tissues share, the process of wound healing also portrays similar characteristics with chronic fibrosis. In this review, we suggest a tight interrelationship, which is governed as a concurrence of cellular and microenvironmental reactivity among wound healing, chronic fibrosis, and cancer development/progression (i.e., the WHFC triad). It is clear that the same cell types, as well as soluble and matrix elements that drive wound healing (including regeneration) via distinct signaling pathways, also fuel chronic fibrosis and tumor progression. Hence, here we review the relationship between fibrosis and cancer through the lens of wound healing.

show abstract

Expression and significance of biglycan in endometrial cancer

Abstract: Biglycan might play a role in the progression of human endometrial cancer and it might be a useful molecular marker for the prognosis of endometrial cancer. This research is an initial step towards biglycan as a potential prognosis marker in endometrial cancer.

Cited by 46 publications

References 14 publications

Biglycan enhances the ability of migration and invasion in endometrial cancer

Biglycan enhances the ability of migration and invasion in endometrial cancer

Altered expression of small leucine-rich proteoglycans (Decorin, Biglycan and Lumican): Plausible diagnostic marker in urothelial carcinoma of bladder

The wound healing, chronic fibrosis, and cancer progression triad

Contact Info

Product

Resources

About